Design and synthesis of isatin derivative payloaded peptide-drug conjugate as tubulin inhibitor against colorectal cancer.

A series of isatin derivatives which could inhibit colorectal cancer (CRC) were synthesized. Among those compounds, 5B exhibited good inhibitory activity of CRC through the inhibition of tubulin expression, inducing apoptosis, and causing G2/M phase cell cycle arrest pathway, which suggested that 5B could be a potential tubulin inhibitor. Based on that, a novel peptide-drug conjugate (PDC), which employed the CRC cells related receptor CD44 ligand peptide A6 coupling to 5B to accomplish A6-5B.

Enhancing Droplet Spreading on a Hydrophobic Plant Surface by Surfactant/Cellulose Nanocrystal Complexes.

A surfactant is an efficient and common additive used to enhance the spreading of droplets on hydrophobic surfaces. However, a high surfactant concentration is required to achieve the desired performance, resulting in environmental pollution and increased costs. Additionally, the pesticide loading capacity of surfactants at low concentrations (below their critical micelle concentrations) is a concern.

Opportunities and limitations of B cell depletion approaches in SLE.

B cell depletion with rituximab, a chimeric monoclonal antibody that selectively targets B cells by binding CD20, has been used off label in severe and resistant systemic lupus erythematosus (SLE) for over two decades. Several biological mechanisms limit the efficacy of rituximab, including immunological reactions towards the chimeric molecule, increased numbers of residual B cells, including plasmablasts and plasma cells, and a post-treatment surge in B cell-activating factor (BAFF) levels. Consequently, rituximab induces remission in only a proportion of patients, and safety issues limit its use.

Extending breast cancer screening beyond age 45-64 years in China: a cost-effectiveness analysis.

The optimal breast cancer (BC) screening age in China remains uncertain. In this study, we evaluated the benefits, harms, and cost-effectiveness of lowering the screening starting age from 45 to 35 years and extending the stopping age from 64 to 79 years in Chinese women at an average risk of progressing BC. Biennial screening showed a lower incremental cost-effectiveness ratio (ICER) compared to annual screening.

Retraction of: Establishment of Tacrolimus-Induced Diabetes in Rat Model and Assessment of Clinical Treatments for Post-Transplant Diabetes Mellitus in Liver Transplant Recipients.

This retracts the article DOI: 10.7754/Clin.Lab.